Ascendis Pharma A/S (ASND) Competitors

BioNTech (NASDAQ:BNTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.

Which has preferable valuation & earnings, BNTX or ASND?

BioNTech has higher revenue and earnings than Ascendis Pharma A/S. BioNTech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.04B	8.80	$1.01B	-$2.10	-53.12
Ascendis Pharma A/S	$363.64M	25.36	-$409.12M	-$7.10	-21.40

Do insiders and institutionals have more ownership in BNTX or ASND?

15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in BNTX or ASND?

Ascendis Pharma A/S received 306 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 66.77% of users gave Ascendis Pharma A/S an outperform vote while only 46.05% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 140 46.05%	Underperform Votes 164 53.95%
Ascendis Pharma A/S	Outperform Votes 446 66.77%	Underperform Votes 222 33.23%

Is BNTX or ASND more profitable?

BioNTech has a net margin of -15.16% compared to Ascendis Pharma A/S's net margin of -104.54%. Ascendis Pharma A/S's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Do analysts prefer BNTX or ASND?

BioNTech currently has a consensus target price of $142.72, suggesting a potential upside of 27.93%. Ascendis Pharma A/S has a consensus target price of $202.36, suggesting a potential upside of 33.19%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Which has more volatility & risk, BNTX or ASND?

BioNTech has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Does the media favor BNTX or ASND?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than BioNTech. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 8 mentions for BioNTech. Ascendis Pharma A/S's average media sentiment score of 0.92 beat BioNTech's score of 0.81 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats BioNTech on 11 of the 18 factors compared between the two stocks.